Senseonics Holdings, Inc. (SENS)

Market Cap	265.24M -53.2%
Revenue (ttm)	35.26M +56.9%
Net Income	-69.11M
EPS	-1.66
Shares Out	41.77M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	301,178
Open	6.42
Previous Close	6.49
Day's Range	6.31 - 6.46
52-Week Range	5.25 - 15.74
Beta	0.98
Analysts	Strong Buy
Price Target	22.70 (+257.48%)
Earnings Date	Mar 2, 2026

About SENS

Senseonics Holdings, Inc., a commercial-stage medical technology company, focuses on development and manufacturing of continuous glucose monitoring (CGM) systems for people with diabetes in the United States and internationally. Its products include Eversense, Eversense XL, Eversense E3, and Eversense 365, which are implantable CGM systems to measure glucose levels in people with diabetes through an under-the-skin sensor, a removable and rechargeable smart transmitter, and an app for real-time diabetes monitoring and management. The company ser...

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 1996
• Employees: 130
• Stock Exchange: NASDAQ
• Ticker Symbol: SENS
• Website: https://www.senseonics.com

Financial Performance

In 2025, Senseonics Holdings's revenue was $35.26 million, an increase of 56.89% compared to the previous year's $22.47 million. Losses were -$69.11 million, -12.09% less than in 2024.

Analyst Summary

According to 5 analysts, the average rating for SENS stock is "Strong Buy." The 12-month stock price target is $22.7, which is an increase of 257.48% from the latest price.

Price Target

$22.7

(257.48% upside)

Analyst Consensus: Strong Buy